How Much Does a Lung Transplant Cost for Treating Lung Cancer?

Lung transplantation is not a treatment for lung cancer. In fact, it is generally contraindicated in patients with active or recently treated non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC). Transplantation is reserved for end-stage, irreversible lung diseases—such as idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, or pulmonary arterial hypertension—where lung function has deteriorated to the point that medical management and other interventions are no longer effective.

In patients with lung cancer, surgical resection—such as lobectomy or pneumonectomy—remains the cornerstone of curative-intent treatment for early-stage disease. For locally advanced or metastatic cancer, systemic therapies including chemotherapy, targeted therapy, immunotherapy, and radiation play critical roles. Lung transplantation does not eliminate malignant cells elsewhere in the body and carries an unacceptably high risk of cancer recurrence post-transplant due to immunosuppression, which impairs immune surveillance against residual or micrometastatic disease.

There are rare, highly selected exceptions—such as patients with synchronous end-stage lung disease and very early-stage, incidentally discovered lung cancer (e.g., stage IA adenocarcinoma found during evaluation for transplant listing)—but even then, transplantation is approached with extreme caution and only after multidisciplinary consensus and rigorous oncologic staging. Survival outcomes in such cases remain poor compared to standard oncologic management.

The cost of lung transplantation in the United States typically exceeds $1.5 million, covering pre-transplant evaluation, surgery, hospitalization, immunosuppressive medications, and long-term follow-up. However, this investment is medically inappropriate—and not covered by insurers—for lung cancer treatment. Patients and families should consult thoracic oncologists and transplant pulmonologists separately to clarify goals of care, eligibility criteria, and evidence-based therapeutic options.